Related Experiment Video
Updated: Aug 8, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Anticoagulation after artificial valve replacement with or without atrial fibrillation: how much is really needed?
1Department of Cardiology, Heartcenter, University Hospital Nijmegen, The Netherlands. f.verheugt@cardio.azn.nl
Thrombosis and Haemostasis
|March 1, 2000
Summary
Mechanical artificial heart valves require lifelong anticoagulation therapy for stroke prevention, with a target International Normalized Ratio (INR) of 2.5-4.5. Bioprosthetic valves necessitate shorter anticoagulation periods unless other conditions exist.
Area of Science:
- Cardiology
- Cardiac Surgery
- Pharmacology
Background:
- Mechanical artificial heart valves necessitate lifelong anticoagulation for thromboembolic event prevention.
- Atrial fibrillation is common in patients with artificial heart valves, influencing anticoagulation strategies.
- Bioprosthetic valves have different anticoagulation requirements compared to mechanical valves.
Purpose of the Study:
- To define optimal anticoagulation strategies for patients with mechanical artificial heart valves.
- To evaluate the role of antiplatelet therapy in reducing thromboembolism.
- To clarify anticoagulation duration for bioprosthetic valve recipients.
Main Methods:
- Review of current guidelines and prospective studies on anticoagulation for artificial heart valves.
- Analysis of International Normalized Ratio (INR) ranges and their impact on outcomes.
- Assessment of adjunctive antiplatelet therapy efficacy.
Main Results:
- Lifelong oral anticoagulation is mandatory for mechanical valves, regardless of atrial fibrillation status.
- Optimal INR range for mechanical valves is 2.5-4.5, requiring further study.
- Bioprosthetic valves require anticoagulation for three months post-surgery if no other indications exist.
Conclusions:
- Mechanical valve replacement mandates lifelong anticoagulation for stroke prevention.
- Further research is needed to refine optimal INR targets and the role of antiplatelet agents.
- Anticoagulation decisions for heart valve recipients should consider valve type, patient comorbidities, and rhythm status.
More Related Videos
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:25Mitral Regurgitation III: Medical Management
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
01:26Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
01:25Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:25Hemodialysis I: Introduction
Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...